[New dry powder inhalers].

[New dry powder inhalers]. Pneumonol Alergol Pol. 2015;83(1):83-7 Authors: Emeryk A, Pirożyński M Abstract The most recently approved DPI's - Ellipta™ and NEXThaler® are the most modern inhalers on the market. Both are flow independent in the physiological range of flows seen in patients with asthma and/or COPD. Both require three actions (open-load -inhaler) for a successful inhalation. The Ellipta™ inhaler is the first DPI, which enables simultaneous delivery of two compounds without need for co-formulation. NEXThaler® is the only DPI on the market delivering extra fine aerosol (MMAD < 2 μm) of a combined inhalation product of inhaled corticosteroid and long-action b2-agonist. Both have been approved world wide for products used in treatment of asthma and COPD. PMID: 25577539 [PubMed - in process]
Source: Pneumonologia i Alergologia Polska - Category: Respiratory Medicine Authors: Tags: Pneumonol Alergol Pol Source Type: research